Inflammatory bowel disease (IBD) comprises primarily the chronic relapsing inflammatory disorders, Crohn's disease and ulcerative colitis, with the former affecting any part of the gastrointestinal tract and the latter mainly afflicting the colon. The precise etiology of IBD remains unclear, and it is thought that interactions among various factors, including genetic factors, the host immune system and environmental factors, cause disruption of intestinal homeostasis, leading to dysregulated inflammatory responses of the gut. As inflammation is intimately related to formation of reactive intermediates, including reactive oxygen and nitrogen species (ROS/RNS), oxidative stress has been proposed as a mechanism underlying the pathophysiology of IBD. This review is intended to summarize succinctly recent new experimental and clinical evidence supporting oxidative stress as a pathophysiological component of IBD and point to the potential of using antioxidant compounds as promising therapeutic modalities of human IBD. The sources of ROS/RNS and the redox signaling mechanism underlying oxidative stress and inflammation in IBD are discussed to provide insight into the molecular basis of oxidative stress as a pathophysiological factor in IBD.
VagefiPA, LongoWE. Colorectal cancer in patients with inflammatory bowel disease. Clin Colorectal Cancer2005;4:313–9
2.
BernsteinCN, FriedM, KrabshuisJH, CohenH, EliakimR, FedailS, GearryR, GohKL, HamidS, KhanAG, LeMairAW, Malfertheiner, OuyangQ, ReyJF, SoodA, SteinwurzF, ThomsenOO, ThomsonA, WatermeyerG. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis2010;16:112–24
3.
AhujaV, TandonRK. Inflammatory bowel disease in the Asia-Pacific area: a comparison with developed countries and regional differences. J Dig Dis2010;11:134–47
4.
MudterJ. What's new about inflammatory bowel diseases in 2011. World J Gastroenterol2011;17:3177
5.
GuidiL, PuglieseD, ArmuzziA. Update on the management of inflammatory bowel disease: specific role of adalimumab. Clin Exp Gastroenterol2011;4:163–72
KhorB, GardetA, XavierRJ. Genetics and pathogenesis of inflammatory bowel disease. Nature2011;474:307–17
8.
KorzenikJR, PodolskyDK. Evolving knowledge and therapy of inflammatory bowel disease. Nat Rev Drug Discov2006;5:197–209
9.
XavierRJ, PodolskyDK. Unravelling the pathogenesis of inflammatory bowel disease. Nature2007;448:427–34
10.
AbrahamC, ChoJH. Inflammatory bowel disease. N Engl J Med2009;361:2066–78
11.
MaloyKJ, PowrieF. Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature2011;474:298–306
12.
PavlickKP, LarouxFS, FuselerJ, WolfRE, GrayL, HoffmanJ, GrishamMB. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. Free Radic Biol Med2002;33:311–22
13.
PravdaJ. Radical induction theory of ulcerative colitis. World J Gastroenterol2005;11:2371–84
14.
KarpSM, KochTR. Oxidative stress and antioxidants in inflammatory bowel disease. Dis Mon2006;52:199–207
15.
ByrneFR, VineyJL. Mouse models of inflammatory bowel disease. Curr Opin Drug Discov Devel2006;9:207–17
16.
MizoguchiA, MizoguchiE. Animal models of IBD: linkage to human disease. Curr Opin Pharmacol2010;10:578–87
17.
TanidaS, MizoshitaT, MizushimaT, SasakiM, ShimuraT, KamiyaT, KataokaH, JohT. Involvement of oxidative stress and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in inflammatory bowel disease. J Clin Biochem Nutr2011;48:112–6
18.
IsmanCA, YegenBC, AlicanI. Methimazole-induced hypothyroidism in rats ameliorates oxidative injury in experimental colitis. J Endocrinol2003;177:471–6
19.
VijayanV, MuellerS, Baumgart-VogtE, ImmenschuhS. Heme oxygenase-1 as a therapeutic target in inflammatory disorders of the gastrointestinal tract. World J Gastroenterol2010;16:3112–9
20.
AbrahamNG, KappasA. Pharmacological and clinical aspects of heme oxygenase. Pharmacol Rev2008;60:79–127
21.
DamianiCR, BenettonCA, StoffelC, BardiniKC, CardosoVH, Di GiuntaG, PinhoRA, Dal-PizzolF, StreckEL. Oxidative stress and metabolism in animal model of colitis induced by dextran sulfate sodium. J Gastroenterol Hepatol2007;22:1846–51
22.
RezaieA, ParkerRD, AbdollahiM. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause?Dig Dis Sci2007;52:2015–21
23.
SeguiJ, GironellaM, SansM, GranellS, GilF, GimenoM, CoronelP, PiqueJM, PanesJ. Superoxide dismutase ameliorates TNBS-induced colitis by reducing oxidative stress, adhesion molecule expression, and leukocyte recruitment into the inflamed intestine. J Leukoc Biol2004;76:537–44
KruidenierL, van MeeterenME, KuiperI, JaarsmaD, LamersCB, ZijlstraFJ, VerspagetHW. Attenuated mild colonic inflammation and improved survival from severe DSS-colitis of transgenic Cu/Zn-SOD mice. Free Radic Biol Med2003;34:753–65
26.
OkuT, IyamaS, SatoT, SatoY, TanakaM, SagawaT, KuribayashiK, SumiyosiT, MuraseK, MachidaT, OkamotoT, MatsunagaT, TakayamaT, TakahashiM, KatoJ, HamadaH, NiitsuY. Amelioration of murine dextran sulfate sodium-induced colitis by ex vivo extracellular superoxide dismutase gene transfer. Inflamm Bowel Dis2006;12:630–40
27.
WatterlotL, RochatT, SokolH, CherbuyC, BouloufaI, LefevreF, GratadouxJJ, Honvo-HuetoE, ChilmonczykS, BlugeonS, CorthierG, LangellaP, Bermudez-HumaranLG. Intragastric administration of a superoxide dismutase-producing recombinant Lactobacillus casei BL23 strain attenuates DSS colitis in mice. Int J Food Microbiol2010;144:35–41
28.
MartenssonJ, JainA, MeisterA. Glutathione is required for intestinal function. Proc Natl Acad Sci USA1990;87:1715–9
29.
EsworthyRS, ArandaR, MartinMG, DoroshowJH, BinderSW, ChuFF. Mice with combined disruption of Gpx1 and Gpx2 genes have colitis. Am J Physiol Gastrointest Liver Physiol2001;281:G848–55
30.
KhorTO, HuangMT, KwonKH, ChanJY, ReddyBS, KongAN. Nrf2-deficient mice have an increased susceptibility to dextran sulfate sodium-induced colitis. Cancer Res2006;66:11580–4
31.
KhorTO, HuangMT, PrawanA, LiuY, HaoX, YuS, CheungWK, ChanJY, ReddyBS, YangCS, KongAN. Increased susceptibility of Nrf2 knockout mice to colitis-associated colorectal cancer. Cancer Prev Res (Phila)2008;1:187–91
32.
MaherJ, YamamotoM. The rise of antioxidant signaling – the evolution and hormetic actions of Nrf2. Toxicol Appl Pharmacol2010;244:4–15
33.
SawCL, KongAN. Nuclear factor-erythroid 2-related factor 2 as a chemopreventive target in colorectal cancer. Expert Opin Ther Targets2011;15:281–95
34.
ArditeE, SansM, PanesJ, RomeroFJ, PiqueJM, Fernandez-ChecaJC. Replenishment of glutathione levels improves mucosal function in experimental acute colitis. Lab Invest2000;80:735–44
35.
PacherP, BeckmanJS, LiaudetL. Nitric oxide and peroxynitrite in health and disease. Physiol Rev2007;87:315–424
36.
RachmilewitzD, StamlerJS, KarmeliF, MullinsME, SingelDJ, LoscalzoJ, XavierRJ, PodolskyDK. Peroxynitrite-induced rat colitis – a new model of colonic inflammation. Gastroenterology1993;105:1681–8
37.
RokutanK, KawaharaT, KuwanoY, TominagaK, NishidaK, Teshima-KondoS. Nox enzymes and oxidative stress in the immunopathology of the gastrointestinal tract. Semin Immunopathol2008;30:315–27
38.
KamizatoM, NishidaK, MasudaK, TakeoK, YamamotoY, KawaiT, Teshima-KondoS, TanahashiT, RokutanK. Interleukin 10 inhibits interferon gamma- and tumor necrosis factor alpha-stimulated activation of NADPH oxidase 1 in human colonic epithelial cells and the mouse colon. J Gastroenterol2009;44:1172–84
39.
DijkstraG, YuvarajS, JiangHQ, BunJC, MoshageH, KushnirN, PeppelenboschMP, CebraJJ, BosNA. Early bacterial dependent induction of inducible nitric oxide synthase (iNOS) in epithelial cells upon transfer of CD45RB(high) CD4(+) T cells in a model for experimental colitis. Inflamm Bowel Dis2007;13:1467–74
40.
ChamulitratW, SpitzerJJ. Generation of nitro and superoxide radical anions from 2,4,6-trinitrobenzenesulfonic acid by rat gastrointestinal cells. Biochim Biophys Acta1997;1336:73–82
NaitoY, TakagiT, YoshikawaT. Molecular fingerprints of neutrophil-dependent oxidative stress in inflammatory bowel disease. J Gastroenterol2007;42:787–98
43.
KlebanoffSJ. Myeloperoxidase: friend and foe. J Leukoc Biol2005;77:598–625
44.
TrevisaniM, SiemensJ, MaterazziS, BautistaDM, NassiniR, CampiB, ImamachiN, AndreE, PatacchiniR, CottrellGS, GattiR, BasbaumAI, BunnettNW, JuliusD, GeppettiP. 4-Hydroxynonenal, an endogenous aldehyde, causes pain and neurogenic inflammation through activation of the irritant receptor TRPA1. Proc Natl Acad Sci USA2007;104:13519–24
45.
KumagaiT, MatsukawaN, KanekoY, KusumiY, MitsumataM, UchidaK. A lipid peroxidation-derived inflammatory mediator: identification of 4-hydroxy-2-nonenal as a potential inducer of cyclooxygenase-2 in macrophages. J Biol Chem2004;279:48389–96
46.
ChristmanJW, BlackwellTS, JuurlinkBH. Redox regulation of nuclear factor kappa B: therapeutic potential for attenuating inflammatory responses. Brain Pathol2000;10:153–62
47.
ChiurchiuV, MaccarroneM. Chronic inflammatory disorders and their redox control: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Signal2011;15:2605–41
48.
PalffyR, GardlikR, BehuliakM, JaniP, BalakovaD, KadasiL, TurnaJ, CelecP. Salmonella-mediated gene therapy in experimental colitis in mice. Exp Biol Med (Maywood)2011;236:177–83
49.
CracowskiJL, BonazB, BessardG, BessardJ, AngladeC, FournetJ. Increased urinary F2-isoprostanes in patients with Crohn's disease. Am J Gastroenterol2002;97:99–103
50.
HatsugaiM, KurokawaMS, KouroT, NagaiK, AritoM, MasukoK, SuematsuN, OkamotoK, ItohF, KatoT. Protein profiles of peripheral blood mononuclear cells are useful for differential diagnosis of ulcerative colitis and Crohn's disease. J Gastroenterol2010;45:488–500
51.
KruidenierL, VerspagetHW. Review article: oxidative stress as a pathogenic factor in inflammatory bowel disease – radicals or ridiculous?Aliment Pharmacol Ther2002;16:1997–2015
52.
CatarziS, FavilliF, RomagnoliC, MarcucciT, PicarielloL, TonelliF, VincenziniMT, IantomasiT. Oxidative state and IL-6 production in intestinal myofibroblasts of Crohn's disease patients. Inflamm Bowel Dis2011;17:1674–84
53.
Krzystek-KorpackaM, NeubauerK, BerdowskaI, ZielinskiB, ParadowskiL, GamianA. Impaired erythrocyte antioxidant defense in active inflammatory bowel disease: impact of anemia and treatment. Inflamm Bowel Dis2010;16:1467–75
54.
MittalRD, ManchandaPK, BidHK, GhoshalUC. Analysis of polymorphisms of tumor necrosis factor-alpha and polymorphic xenobiotic metabolizing enzymes in inflammatory bowel disease: study from northern India. J Gastroenterol Hepatol2007;22:920–4
55.
HertervigE, NilssonA, SeidegardJ. The expression of glutathione transferase mu in patients with inflammatory bowel disease. Scand J Gastroenterol1994;29:729–35
56.
KarbanA, HartmanC, EliakimR, WatermanM, NesherS, Barnett-GrinessO, ShamirR. Paraoxonase (PON)1 192R allele carriage is associated with reduced risk of inflammatory bowel disease. Dig Dis Sci2007;52:2707–15
57.
KosakaT, YoshinoJ, InuiK, WakabayashiT, KobayashiT, WatanabeS, HayashiS, HirokawaY, ShiraishiT, YamamotoT, TsujiM, KatohT, WatanabeM. Involvement of NAD(P)H:quinone oxidoreductase 1 and superoxide dismutase polymorphisms in ulcerative colitis. DNA Cell Biol2009;28:625–31
58.
de JongDJ, van der LogtEM, van SchaikA, RoelofsHM, PetersWH, NaberTH. Genetic polymorphisms in biotransformation enzymes in Crohn's disease: association with microsomal epoxide hydrolase. Gut2003;52:547–51
59.
ArisawaT, TaharaT, ShibataT, NagasakaM, NakamuraM, KamiyaY, FujitaH, YoshiokaD, OkuboM, SakataM, WangFY, HirataI, NakanoH. Nrf2 gene promoter polymorphism is associated with ulcerative colitis in a Japanese population. Hepatogastroenterology2008;55:394–7
GuijarroLG, MateJ, GisbertJP, Perez-CalleJL, Marin-JimenezI, ArriazaE, OllerosT, DelgadoM, CastillejoMS, Prieto-MerinoD, Gonzalez LaraV, PenaAS. N-acetyl-L-cysteine combined with mesalamine in the treatment of ulcerative colitis: randomized, placebo-controlled pilot study. World J Gastroenterol2008;14:2851–7
62.
HanaiH, SugimotoK. Curcumin has bright prospects for the treatment of inflammatory bowel disease. Curr Pharm Des2009;15:2087–94
63.
MeyerCT, BrandM, DeLucaVA, SpiroHM. Hydrogen peroxide colitis: a report of three patients. J Clin Gastroenterol1981;3:31–5
